

Role of oncology pharmacist in Car-T cells-management

Vito Ladisa – Director Hospital Pharmacy

National Cancer Institute of Milan (IRCCS Istituto Nazionale dei Tumori di Milano) Italy

The introduction of CAR-T, recognized as an international drug, sees a new role for the oncology hospital pharmacist, who not only ensures access to therapy, but represents an important achievement in the CAR-t Team. The management of CAR T, if we imagine the patient's journey, includes the pharmacist's own activities that must be strongly integrated with the Clinician's activity, think of lymphodepleting therapy or bridging therapies that are set up in our laboratories, according to quality and safety standards, but which must respect timelines and chronology that cannot foresee delays. As a member of the CAR-T Team, the pharmacist must be part of the multidisciplinary group for post-infusion monitoring of the patient and therefore Pharmacy organization must provide for the availability of antidotes for foreseeable adverse events, as well as provide for possible off-label therapeutic alternatives in the absence or non-response of tocilizumab. We will have to share the risks associated with polypharmacy with the doctor Therefore an all-round role that requires deep knowledge of the drug and great willingness to share experiences and skills

ROLE OF ONCOLOGY PHARMACIST IN CAR-T MANAGEMENT

Julya Zuenkova, Russian Federation

The development and commercialization of CAR-T represent a new challenge for a hospital pharmacy. The regulatory aspects of CAR-T in some countries are analysed. The aim is to describe the oncohematology pharmacist's role within the multidisciplinary clinical team. This includes the different phases in the transversal process that involves a therapy with CAR-T medicines, ranging from indication to short and long term follow-up of patients, and emphasizing on the management of its main adverse effects. The key aspects of the successful multidisciplinary teams (MDT) are emphasized. The key processes of CAR-T therapy is described together with standard operational procedures (SOP) guidelines for the oncology pharmacist. CAR-T therapy offers the hospital pharmacist the opportunity to work closely with the clinical professionals involved in the process, allowing their contribution to the development of procedures, clinical practice guidelines of global approach, and establishing starting points when facing future therapies of similar complexity and even improving previously established basic processes. The educational path for oncology pharmacist for management CAR-T is not universe in some countries that generate a need for learning opportunities within the clinical place.